Professor
Phone: (239) 590-7439
E-Mail: smichael@fgcu.edu
Office: AB7 307

Scott F. Michael is a Professor in the Department of Biological Sciences. He completed his Bachelor’s degree in biology and chemistry at Cornell College in Mount Vernon, IA, received his Ph.D. in chemistry from the Johns Hopkins University and did postdoctoral training in molecular virology at the University of North Carolina at Chapel Hill and the University of Alabama at Birmingham. Prior to being recruited to FGCU in 2004, he was a faculty member in the Department of Tropical Medicine at Tulane University. His current research interests include the development and study of entry inhibitors against viral pathogens. Dr. Michael has received research support from the National Science Foundation, the National Institutes of Health, the Department of Defense, and the US Department of Agriculture.

Teaching Interests: Cell Biology, Virology

Research Interests: Antiviral and vaccine strategies, Virus evolution, Viral drug resistance

Recent Publications: (*FGCU graduate)

• Graham AS, Pruszynski CA, Hribar LJ, DeMay DJ, Tambasco AN, Hartley AE, Fussell EM, Michael SF, Isern S. “Mosquito-associated dengue virus, Key West, Florida, USA, 2010”, Emerging Infectious Diseases, 2011 vol. 17, no. 11, p. 2074-2075, http://dx.doi.org/10.3201/eid1711.110419
• Schieffelin JS, Costin JM, *Nicholson CO, Orgeron NM, *Fontaine KA, Isern S, Michael SF, Robinson JE. “Neutralizing and non-neutralizing human monoclonal antibodies against dengue virus E protein from a naturally infected patient”, Virology Journal 2010, 7:28. doi:10.1186/1743-422X-7-28
• Costin JM, Jenwitheesuk E, *Rees CR, Hunsperger E, Conrads K, *Fontaine KA, Isern S, Samudrala R, Michael SF. “Structural Optimization and De Novo Design of Dengue Virus Entry Inhibitory Peptides”, PLoS Neglected Tropical Diseases, 2010 4(6): e721. doi:10.1371/journal.pntd.0000721.
• *Nicholson CO, Costin JM, *Rowe DK, Lin L, Jenwitheesuk E, Samudrala R, Isern S, Michael SF. “Viral entry inhibitors block dengue antibody-dependent enhancement in vitro”, Antiviral Research 89:71–74 (2011).